Atezolizumab 1200 mg abs day 1 q22 (iv) clinical trials

Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC

This study looks at a new way to treat certain lung cancers before surgery. We want to see how well a combination of medicines works and if we can predict who will benefit most. It's for people aged 18 and over with specific types of non-small cell lung cancer.